Behavioral Health Psychotropics

Printing and PDF export are disabled for this protected preview. Continue reading inside the DiraChart reader.

Trace DC53-15

DiraChart Clinical Reference
Protected section 15 of 15
← Document menu
Nursing Home · DiraChart

1. Purpose and clinical relevance

DiraChart Clinical Reference

Section NavigationPart 15 of 15PreviousDocument Menu

12. Sources and clinical references

  • 42 CFR 483 §483.40 (behavioral health services) and §483.45 (unnecessary drugs; psychotropics; GDR; PRN limits) with State Operations Manual Appendix PP F740–F745, F758, F604/F605.
  • CMS MDS 3.0 RAI User’s Manual v1.20.1 (eff. 1 Oct 2025), Sections C/D/E/N; MDS 3.0 QM User’s Manual v18.0 (eff. 1 Jan 2026, long-stay antipsychotic respecification).
  • CMS National Partnership to Improve Dementia Care in Nursing Homes (antipsychotic-reduction guidance).
  • CMS Pub. 100-02 Chapter 8 (skilled observation/management). DiraChart Foundations 1.1–1.11.

Standing flags. Model notes are scaffolds — fill with the shift’s actual values and confirm every threshold against current orders and the care plan. Coverage rules, MDS item sets, and F-tag guidance change; verify against the current published source. MAC/LCD and accreditation items are facility-fill.

Section NavigationPart 15 of 15PreviousDocument Menu